We were sitting in the Irish pub on quiz night, dumbfounded by trivia questions about ingredients of Mornay sauce and best‐selling Boy Bands, when the following question came up: What are 'Live microorganisms which when administered in adequate amounts confer a health benefit on the host?' At long last, we had a correct answer: PROBIOTICS! The quizmaster was totally disinterested in our extensive elaboration on this topic, so we offer it to the readers of this Genomics Update.

The Russian Noble Prize winner Elie Metchinkoff first suggested that certain bacteria could modify the composition of the gut flora ([@b29]). He suggested that the longevity of Bulgarians and Russians of the Steppes was due to their consumption of 'sour milk' containing beneficial microbes, which in fact probably were lactic acid bacteria (LAB) such as *Lactobacillus bulgaricus*. Henry Tissier of the Pasteur Institute isolated bacteria (now called *Bifidobacterium bifidum*) from the faeces of healthy breast‐fed infants and recommended giving it to babies suffering from diarrhoea ([@b39]). In 1935, Minoru Shirota in Japan developed the first commercial probiotic drink called Yakult, which contains *Lactobacillus casei* Shirota that can survive the passage through the stomach and colonize the intestine. The probiotic market is now estimated to be worth about \$6 000 000 000 a year and is growing at around 10% annually ([@b41]). Since 1981 there have been over 2000 patent applications on probiotics filed (with 'probiotic' mentioned in patent somewhere) and some 524 granted (in the USA and Europe). The two most commonly used probiotics in commercial products are lactobacilli, members of the LAB, and bifidobacteria, but some yeasts and other bacteria have been claimed to have probiotic potential. See [Table 1](#t1){ref-type="table"} and [@b33]) for an overview of commercially used strains and their claimed probiotic effects.

###### 

Examples of commercial probiotic strains and products (adapted from http://en.wikipedia.org/wiki/Probiotic\#cite_note‐48).

  Species/strain                                                       Brand name                                 Producer                    Claimed effect in humans/animals
  -------------------------------------------------------------------- ------------------------------------------ --------------------------- ----------------------------------------------------------------------------------------------------------------
  *Bacillus coagulans* GBI‐30, 6086                                    GanedenBC^30^                              Ganeden Biotech             Improves abdominal pain and bloating in IBS patients. Increases immune response to viral challenge
  *Bifidobacterium animalis* ssp. *lactis* BB‐12                       BB‐12                                      Chr. Hansen                 Reduction in *Strept. mutans* in mouth; IBS amelioration in a multispecies trial
  *Bifidobacterium animalis* ssp. *lactis* HN019 (DR10)                Howaru Bifido                              Danisco                     Reduced prevalence of atopy and eczema in the first 2 years of life
  *Bifidobacterium breve* Yakult                                       Bifiene                                    Yakult                      Ulcerative colitis amelioration
  *Bifidobacterium infantis* 35624                                     Align                                      Procter & Gamble            Irritable bowel syndrome treatment
  *Bifidobacterium longum* BB536                                       BB536                                      Morinaga                    Treatment of allergy, especially Japanese cedar pollinosis
  *Escherichia coli* M‐17                                              ProBactrix                                 BioBalance                  Irritable bowel syndrome treatment
  *Escherichia coli* Nissle 1917                                       Mutaflor                                   Ardeypharm                  Enterocolitis, remission of ulcerative colitis
  *Lactobacillus acidophilus* DDS‐1                                    DDS‐1                                      Nebraska Cultures           Alleviation of traveller\'s diarrhoea; vitamin production
  *Lactobacillus acidophilus* LA‐5                                     LA‐5                                       Chr. Hansen                 Alleviation of acute diarrhoea
  *Lactobacillus acidophilus* NCFM                                     Howaru acidophilus                         Danisco                     Improvement of intestinal health, treatment of vaginal/urogential infections
  *Lactobacillus acidophilus* GAL‐2                                    Ghenisson 22                               GHEN Co                     Improves digestive health in poultry
  *Lactobacillus brevis* KB290                                         LABRE                                      Kagome                      Improvement of bowel movement, enhances NK activity and interferon‐α activity
  *Lactobacillus casei* DN114‐001                                      Actimel, DanActive                         Danone                      Acute diarrhoea treatment; infection prevention; gut development
  *Lactobacillus casei* CRL431                                         CRL431                                     Chr. Hansen                 Immune stimulation, Alleviation of acute diarrhoea
  *Lactobacillus casei* F19                                            Cultura                                    Arla Foods                  Improvement in bowel function
  *Lactobacillus casei* Shirota                                        Yakult                                     Yakult                      Alleviation of acute diarrhoea
  *Lactobacillus paracasei* St11                                       Lactobacillus fortis                       Nestlé                      Natural defence/immune system, gut health
  *Lactobacillus johnsonii* NCC533                                     LC1 range                                  Nestlé                      Immunomodulation; pathogen inhibition
  *Lactococcus lactis* L1A                                             VERUM HÄLSOFIL                             Norrmejerier                Immune stimulation; improves digestive health; reduces antibiotic‐associated diarrhoea
  *Lactobacillus plantarum* 299v                                       GoodBelly, ProViva, TuZen                  NextFoods, Probi, Ferring   Iron absorption
  *Lactobacillus reuteri* ATTC 55730                                   L. reuteri Protectis                       BioGaia Biologics           Diarrhoea prevention and mitigation; eradication of *H. pylori* infection; amelioration of gingivitis.
  *Lactobacillus rhamnosus* GG                                         Vifit and others                           Valio                       Immune stimulation; alleviates atopic eczema; prevents diarrhoea in children and many other types of diarrhoea
  *Lactobacillus rhamnosus* LB21                                       Verum                                      Norrmejerier                
  *Lactobacillus rhamnosus* GR‐1 & *Lactobacillus reuteri* RC‐14       Bion, Flore, Intime, Jarrow, Fem‐Dophilu   Chr. Hansen                 Vaginal colonization and prevention of vaginitis
  *Lactobacillus acidophilus* NCFM & *Bifidobacterium bifidum* BB‐12   Florajen3                                  American Lifeline, Inc      Reduction of *C. difficile*--associated disease (CDAD)
  *Lactobacillus acidophilus* CL1285 & *Lactobacillus casei*           Bio‐K+ CL1285                              Bio‐K+ International        Improves digestive health; prevents Antiobic Associated Diarrhea (AAD; inhibition of pathogens
  *Lactobacillus acidophilus* MNFLM01 & *Enterococcus faecium*         LAB‐MOS                                    Alltech                     Lowers pathogen numbers in lamb intestine
  *Lactobacillus helveticus* R0052 & *Lactobacillus rhamnosus* R0011   A\'Biotica and others                      Institut Rosell             *Helicobacter pylori* inhibition

For several other products with mixtures of probiotic bacteria see [http://en.wikipedia.org/wiki/Probiotic\#cite_note‐48](http://en.wikipedia.org/wiki/Probiotic#cite_note‐48).

Probiotic mechanisms
====================

What do probiotics actually do? What is the meaning of 'confer a health benefit'? Probiotics are most commonly known as yoghurts or yoghurt‐type drinks that people ingest. The consumption of probiotics by humans is intended to improve or maintain a healthy intestine. The claimed modes of action of probiotics include strengthening of the intestinal barrier function, modulation of immune responses, supply of vitamins, and antagonism of pathogens (or other commensals) either by producing antimicrobials or by binding to the mucosa (so called competitive exclusion). (For recent reviews see [@b26]; [@b44]; [@b13]; [@b23]; [@b1001].) In general, desired attributes of probiotic strains include adequate survival of the stomach passage (i.e. low pH stability), and adaptation to the host gut environment, including stress response, active and synergistic metabolism, and adherence to the intestinal mucosa and mucus. Probiotics are presumed to have an ecological advantage owing to their capacity to metabolize complex sugars that are derived from the diet as well as from the host. Sugar metabolism enzymes include various glycosyl hydrolases (GHs) which can degrade plant‐derived dietary fibres or complex host carbohydrate structures. Bacteriocin production may enhance their competitiveness in the gut. From an industrial perspective, crucial attributes of probiotic strains are good technological properties for production and storage and low health risk to consumers.

Probiotics need not be restricted to food applications or oral delivery. Some can be applied to the skin as lotions or cream ([@b20]) and have been used to treat vaginal infections ([@b35]). Probiotics are also added to animal and fish feed to enhance growth, replacing the banned additive antibiotics or growth hormones ([@b8]; [@b12]; [@b48]). They appear to work by inhibiting/reducing the pathogenic bacterial load that some animals or fish carry. There is evidence for all of these probiotic modes, but the exact mechanisms of action are still not very clear. Genome‐scale analyses of health‐promoting bacteria, also coined 'probiogenomics' ([@b45]), should provide clues for probiotic mechanisms and potential. Here, we provide an update of recent genomics studies in this field.

Genome sequencing
=================

[Table 2](#t2){ref-type="table"} and [Fig. 1](#f1){ref-type="fig"} give an overview of genome sequencing of putative probiotic bacteria that are publicly available, and [Table 3](#t3){ref-type="table"} gives examples of proprietary sequences of commercial probiotics. By far the most used probiotics and the ones which have their genomes sequenced are those associated with gut health. Details of genomes sequenced before 2009 have been summarized by [@b28]) and [@b45]). Infants are born with a sterile gastrointestinal (GI) tract but in breast‐fed babies colonization by bifidobacteria is rapidly seen. It is thought that these bacteria confer a health benefit to the infant. The first colonizer is *Bifidobacterium longum* ssp. *infantis*, which has the largest genome of any sequenced bifidobacteria at 2.83 Mb ([@b37]). The genome has complete pathways for the synthesis of some vitamins and a novel 43 kb gene cluster encoding a system for the import and degradation of human milk oligosaccharides (HMOs). After weaning, the numbers of this bifidobacterium decline but others become more dominant. *Bifidobacterium animalis* ssp. *lactis*, a resident of the GI tract and the most commonly used probiotic in Europe and North America, has a genome size of only 1.9 Mb. These bifidobacteria lack the HMO cluster as presumably post‐weaned animals no longer require this functionality. They do, however, contain the *fos* gene cluster necessary to produce the enzymes to break down and utilize health‐promoting fructo‐oligosaccharides, a well‐known prebiotic and bifidogenic factor.

###### 

Publicly available sequenced complete genomes of (putative) probiotic bacteria (adapted from the GOLD Database (<http://www.genomesonline.org>; October 2009).

  Species                                          Strain          Accession   Isolation source              Reference
  ------------------------------------------------ --------------- ----------- ----------------------------- ------------------------------------------
  ACTINOBACTERIA                                                                                             
  * Bifidobacterium adolescentis*                  ATCC 15703      NC_008618   Human faeces                  Unpublished; Gifu University, Japan
  * Bifidobacterium animalis* ssp. *lactis*        AD011           NC_011835   Human infant faeces           [@b16])
  * Bifidobacterium animalis* ssp. *lactis*        ATCC SD5219     NC_012814   Human infant faeces           [@b2])
  * Bifidobacterium animalis* ssp. *lactis*        DSM 10140       NC_012815   Swiss yoghurt                 [@b2])
  * Bifidobacterium breve*                         UCC203                                                    [@b22])
  * Bifidobacterium longum*                        NCC2705         NC_004307   Human infant faeces           [@b36])
  * Bifidobacterium longum*                        DJO10A          NC_010816   Human adolescent faeces       [@b24])
  * Bifidobacterium longum* ssp. *infantis*        ATCC 15697      NC_011593   Human infant faeces           [@b37])
  * Propionibacterium freundenreichii*             ATCC9614                    Swiss cheese                  Unpublished; INRA, Rennes, France
  FIRMICUTES                                                                                                 
  * Lactobacillus acidophilus*                     NCFM            NC_006814   Human intestine               [@b1])
  * Lactobacillus casei*                           ATCC 334        NC_008526   Emmental cheese               [@b25])
  * Lactobacillus casei*                           BL23            NC_010999                                 Unpublished; INRA, Jouy‐en‐Josas, France
  * Lactobacillus delbrueckii* ssp. *bulgaricus*   ATCC BAA‐365    NC_008529   French starter culture        [@b25])
  * Lactobacillus delbrueckii* ssp. *bulgaricus*   ATCC 11842      NC_008054   Bulgarian yoghurt             [@b43])
  * Lactobacillus fermentum*                       IFO 3956        NC_010610   Japanese fermented plant      [@b31])
  * Lactobacillus gasseri*                         ATCC 33323      NC_008530   Human intestine               [@b25])
  * Lactobacillus helveticus*                      DPC 4571        NC_010080   Swiss cheese                  [@b5])
  * Lactobacillus johnsonii*                       NCC533          NC_005362   Human intestine               [@b34])
  * Lactobacillus johnsonii*                       FI9785          FN298497    Poultry                       [@b46])
  * Lactobacillus plantarum*                       WCFS1           NC_004567   Human saliva                  [@b19])
  * Lactobacillus plantarum*                       JDM1            NC_012984                                 [@b49])
  * Lactobacillus reuteri*                         F275, JCM1112   NC_010609   Human adult intestine         [@b31])
  * Lactobacillus rhamnosus*                       GG              NC_013198   Human faeces                  [@b14])
  * Lactobacillus rhamnosus*                       ATCC53103       AP011548    Human intestine               [@b30])
  * Lactobacillus salivarius*                      UCC118          NC_007929   Human small intestine         [@b6])
  * Leuconostoc citreum*                           KM20            NC_010471   Korean fermented vegetables   [@b15])

In the 'Ongoing genome sequencing projects' (<http://www.genomesonline.org/gold.cgi?want=Bacterial+Ongoing+Genomes#>) in the GOLD database, another 45 *Bifidobacterium* and 98 *Lactobacillus* strains are listed; incomplete genome sequence data is already publicly available for 10 and 34 of these strains respectively. Although many are gut isolates, not all will represent probiotic strains.

![Evolutionary relationships between the main gastrointestinal tract commensal lactobacilli, based on a neighbour‐joining tree of 16S rRNA gene sequences. Bootstrap values above 600 are indicated. Bacterial taxa for which whole genome sequences are available are shaded in green. The outgroup is shaded in grey. Lactobacilli for which genome sequencing is ongoing/incomplete are shaded in red. Reproduced and adapted from [@b45]), with permission from Macmillan Publishers Limited, 2009.](mbt0003-0001-f1){#f1}

###### 

Proprietary genome sequences of commercial (putative) probiotic bacteria.

  Species                                     Strain      Genome size (Mb)   Company                Reference
  ------------------------------------------- ----------- ------------------ ---------------------- --------------------------------------------------------------------------------------
  ACTINOBACTERIA                                                                                    
  * Bifidobacterium animalis* ssp. *lactis*   BB‐12       2.0                Chr. Hansen, Denmark   [christel.garrigues\@dk.chr‐hansen.com](mailto:christel.garrigues@dk.chr‐hansen.com)
  * Bifidobacterium breve*                    Yakult      2.35               Yakult, Japan          [yukio‐shirasawa\@yakult.co.jp](mailto:yukio‐shirasawa@yakult.co.jp)
  * Bifidobacterium breve*                    M‐16V       2.3                Morinaga Milk, Japan   <k_nanba@morinagamilk.co.jp>
  * Bifidobacterium longum* biot *infantis*   M‐63        2.8                Morinaga Milk, Japan   <k_nanba@morinagamilk.co.jp>
  * Bifidobacterium longum*                   BB536       2.5                Morinaga Milk, Japan   <k_nanba@morinagamilk.co.jp>
  * Bifidobacterium lactis*                               1.94               Danone, France         <tamara.smokvina@danone.com>
  FIRMICUTES                                                                                        
  * Lactobacillus brevis*                     KB290       2.49               Kagome, Japan          <masanori_fukao@kagome.co.jp>
  * Lactobacillus casei*                      Shirota     3.03               Yakult, Japan          [yukio‐shirasawa\@yakult.co.jp](mailto:yukio‐shirasawa@yakult.co.jp)
  * Lactobacillus casei*                                  3.14               Danone, France         <tamara.smokvina@danone.com>
  * Lactobacillus reuteri*                    ATCC55730   2.0                SLU, Sweden            <klara.bath@mikrob.slu.se>

Source: Abstracts Symposium on Lactic Acid Bacteria 2005 and 2008, Egmond aan Zee, the Netherlands.

Several new genome sequences of probiotics have been released in 2009. *Bifidobacterium animalis* ssp. *lactis* AD011, isolated from a healthy breast‐fed infant, has a high level of immunomodulatory activity ([@b17]). Its genome encodes multiple glycosylases than can degrade plant‐ or milk‐derived oligosaccharides, and the *fos* gene cluster for processing of fructo‐oligosaccharides ([@b16]). *Bifidobacterium animalis* ssp. *lactis* strains B1‐04 and DSM10140, both from commercial probiotic products, differ only by 47 single nucleotide polymorphisms and four small indels, of which one indel in a CRISPR ([@b2]). *Lactobacillus johnsonii* FI9785 is a competitive exclusion agent against pathogens in poultry ([@b46]). *Lactobacillus plantarum* JDM1 is a widely used Chinese commercial probiotic strain which appears to have lost 100 kb relative to the non‐commercial strain WCFS1, encoding sugar transport and metabolism, possibly due to prolonged growth of this probiotic strain in rich medium ([@b49]). *Lactobacillus rhamnosus* GG and *Lactobacillus rhamnosus* ATCC53103, probiotic strains used widely for nearly 20 years in a variety of functional foods, differ only by deletion of 5 kb in ATCC53103, and an inversion of 8.9 kb ([@b14]; [@b30]). Compared with other sequenced intestinal lactobacilli, both *Lb. rhamnosus* genomes have a relatively high number of proteins involved in carbohydrate and amino acid metabolism and transport, and defence mechanisms. In particular, 28 complete PTS‐type transporters and 25 putative GHs are encoded, including the alpha‐L‐fucosidase (GH29; see Cazy database <http://www.cazy.org>) and alpha‐mannosidase (GH38) families, which are not found in other sequenced lactobacilli. In addition, these *Lb. rhamnosus* genomes have three gene clusters encoding proteins with WxL domains which can attach to the peptidoglycan on cell surfaces ([@b38]; [@b3]); again, these gene clusters have not been found in other intestinal lactobacilli, but rather in plant‐associated Gram‐positive bacteria ([@b38]). Most novel is the finding that *Lb. rhamnosus* GG has a gene cluster *spaCBA*, encoding three secreted pilin proteins with LPxTG‐type peptidoglycan anchors, which is not present in the highly syntenous genome of *Lb. rhamnosus* LC705 ([@b14]). SpaA is the major scaffolding protein upon which the minor pili proteins SpaB and SpaC are attached. Using insertional inactivation of *spaC*, a truncated SpaC protein was produced which resulted in cells with a greatly reduced binding to human mucus ([@b14]). The authors suggest that the presence of SpaC‐containing pili ([Fig. 2](#f2){ref-type="fig"}) may possibly explain the longer persistence of this strain in the GI tract than strain LC705. Together with the high potential for sugar uptake and metabolism, this may explain probiotic effects of these *Lb. rhamnosus* strains.

![Identification of pili in *L. rhamnosus* GG by immunogold high‐resolution electron micrography. Multiple pili are shown with gold‐labelled SpaC proteins. Reproduced with permission from [@b14]).](mbt0003-0001-f2){#f2}

Experimental omics exploration of molecular mechanisms
======================================================

Ingested probiotic microbes themselves will react to the new environment of the intestine and change their gene expression accordingly. Transcriptional responses of bifidobacteria to human and formula milk have been described in *in vitro* and *in vivo* experiments, the latter from faecal samples of infants ([@b10]; [@b18]). Carbohydrate metabolism genes are commonly upregulated, and include enzymes for degradation of complex plant carbohydrates, which are poorly digested by the host or other intestinal microbes ([@b18]), and for metabolism of mucin and HMOs ([@b10]). In addition, putative genes were upregulated for cell‐surface type 2 glycoprotein‐binding fimbriae that are implicated in attachment and colonization in the intestine ([@b10]).

*In vitro* transcriptional response of *Lactobacillus reuteri* ATCC55730, a strain marketed for probiotic usage, to bile stress has been described ([@b47]). Upregulation was seen for genes involved in multidrug transport, membrane/cell wall stress, oxidative stress, DNA damage and protein denaturation. Transcription and comparative genomics analysis of *Lb. johnsonii* NCC533, an isolate characterized by long gut persistence, identified three genetic loci that were specifically expressed in the jejunum of mice mono‐colonized with this strain, encoding a PTS‐type sugar transporter, glycosyltransferases and an IgA‐type protease ([@b7]). Several years ago, a very elegant resolvase‐based *in vivo* expression technology was developed to study specific *in vivo* gene expression in *L. plantarum* WCFS1, using the mouse GI tract as a model system ([@b4]). This has now been followed up by whole genome transcriptome profiling of strain WCFS1 during colonization of the caeca of germ‐free mice fed either standard low‐fat rodent diet rich in complex plant polysaccharides or a Western diet rich in simple sugars and fats ([@b27]). Numerous carbon metabolism pathways of *L. plantarum* were upregulated on both diets, including uptake and utilization of raffinose, cellulose, maltose, lactose/galactose, sucrose, melibiose, sugar alcohols and sialic acid. Sialic acid is a common component of (human) gut glycoproteins.

Host responses to potential probiotics have recently been described in intervention studies in healthy human volunteers. Duodenal mucosa was sampled after intraduodenal infusion ([@b40]) or oral ingestion ([@b42]) of *L. plantarum* WCFS1. The continuous perfusion study showed that after prolonged exposure, mucosal cells switched to a more proliferative phase with upregulation of genes involved in lipid metabolism, cellular growth and development. Cell death and immune responses were triggered, but cell‐death executing cells or inflammatory signals were not expressed. In the second study, consumption of live *L. plantarum* cells showed striking modulation of NF‐κB‐dependent pathways in mucosal cells, and identified cellular pathways that correlated with the establishment of immune tolerance in healthy adults ([@b42]). [Figure 3](#f3){ref-type="fig"} summarizes some of the mechanistic events underlying probiotic effects that are beginning to be understood from these *in vitro* and *in vivo* studies.

![Bacterial and host effector molecules with potential probiotic effects. *Lactobacillus* strains are able to induce IL‐10‐producing, regulatory T cells (T reg) through DC‐SIGN interaction (1). They can also induce hyporesponsive CD4^+^ T‐cell populations after DC interaction (2). Lipoteichoic acid (LTA) composition is responsible for the differential modulation of cytokine production (3). Modulation of inflammatory responses by inactivation of the NF‐κB signalling pathway is achieved through proteasome inhibition after IEC recognition of soluble probiotic components (4) or after recognition of bacterial motifs (e.g. CpG DNA by TLR9 receptors) (6). The induction of Hsps (either via 4 or 5) stabilizing the actin cytoskeleton would strengthen the mucosal barrier. Pathogen attachment and growth could be counteracted by strains possessing mannose adhesins (7) or by induction of hBD2 in IECs (8). M cell is an epithelial cell specialized in antigen uptake and transport. Reproduced and adapted with permission from [@b26]), Elsevier Ltd.](mbt0003-0001-f3){#f3}

Adaptation of probiotic strains
===============================

*Bifidobacterium longum* DJO10A, an intestinal isolate, was shown to lose functionality by gene loss after prolonged pure culture ([@b24]). It would appear that when growing in the competitive environment of the colon the cells retained some important functionalities predicted to be involved in diverse traits pertinent to the human intestinal environment, specifically oligosaccharide and polyol utilization, arsenic resistance and bacteriocin production. The targeted loss of genomic regions was experimentally validated when growth of the intestinal *B. longum* in the laboratory for 1000 generations resulted in two large deletions, one in a bacteriocin‐encoding region, analogous to a predicted deletion event in the commercial strain *B. longum* NCC2705 ([@b32]). This deletion strain showed a significantly reduced competitive ability against *Clostridium difficile* and *Escherichia coli*. The deleted region was between two IS30 elements which were experimentally demonstrated to be hyperactive within the genome. Hence, deletion of genomic regions, often facilitated by mobile elements, allows bifidobacteria to adapt to fermentation environments in a very rapid manner (two genome deletions per 1000 generations) and the concomitant loss of possible competitive abilities in the gut. This has implications for industry, because the claims for the use of a probiotic need to be fully substantiated.

Future
======

One of the most remarkable probiotic discoveries was made by the German Alfred Nissle in 1917 in World War I. Life in the trenches was dangerous and not just from the fighting. Disease was rife, especially enterocolitis (inflammation of the small and large intestine) caused by outbreaks of shigellosis. One soldier did not succumb to the disease and Nissle isolated from his faeces a bacterium with which he successfully treated other soldiers. *Escherichia coli* Nissle 1917 is still in use and is one of the few examples of a non‐LAB probiotic (Mutaflor) ([Table 1](#t1){ref-type="table"}). At present, many of the commercial probiotic strains originate from the intestine of healthy infants and adults. Current research focuses on the determination of the characteristics these bacteria use to survive and compete successfully in the intestine, and with this knowledge more effective probiotic strains can be identified. To speed up this search, numerous gut metagenomic sequencing efforts are ongoing world‐wide to identify potential new probiotic candidates ([@b9]; [@b21]). See also the Human Gut Metagenome Initiative (<http://www.international.inra.fr/press/mapping_the_human_intestinal_metagenome>) and the Human Gut Microbiome Initiative ([@b11]) (<http://genomeold.wustl.edu/hgm/HGM_frontpage.cgi>). Perhaps the future will bring us health‐promoting drinks containing mixtures of many probiotic strains, much like the cocktails used these days for vaccination against infectious diseases. And what will be the next hype? Memory‐enhancing drinks would definitely be a commercial success on quiz night in the pub!
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